P3 Health Partners Inc.
Get $10 bonus on your first $100 deposit for PIII
Get $10 bonus on your first $100 deposit for PIII
P3 Health Partners Inc. (PIII) Stock Competitors & Peer Comparison
See (PIII) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PIII | $2.45 | +3.81% | 8.1M | -0.05 | -$45.26 | N/A |
| HCA | $492.58 | -0.97% | 111.5B | 17.59 | $28.34 | +0.59% |
| THC | $198.34 | +2.77% | 17.3B | 12.69 | $15.50 | N/A |
| FMS | $23.00 | -3.04% | 13.4B | 11.80 | $1.97 | +3.38% |
| SOLV | $68.68 | +1.88% | 12B | 7.77 | $8.88 | N/A |
| UHS | $180.37 | -1.55% | 11.6B | 7.88 | $23.10 | +0.44% |
| ENSG | $197.38 | -1.46% | 11.5B | 34.04 | $5.83 | +0.13% |
| EHC | $106.64 | -0.86% | 10.7B | 19.23 | $5.55 | +0.69% |
| DVA | $146.07 | -3.62% | 10B | 15.72 | $9.51 | N/A |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
Stock Comparison
PIII vs HCA Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, HCA has a market cap of 111.5B. Regarding current trading prices, PIII is priced at $2.45, while HCA trades at $492.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas HCA's P/E ratio is 17.59. In terms of profitability, PIII's ROE is +8.94%, compared to HCA's ROE of -1.41%. Regarding short-term risk, PIII is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check HCA's competition here
PIII vs THC Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, THC has a market cap of 17.3B. Regarding current trading prices, PIII is priced at $2.45, while THC trades at $198.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas THC's P/E ratio is 12.69. In terms of profitability, PIII's ROE is +8.94%, compared to THC's ROE of +0.35%. Regarding short-term risk, PIII is more volatile compared to THC. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check THC's competition here
PIII vs FMS Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, FMS has a market cap of 13.4B. Regarding current trading prices, PIII is priced at $2.45, while FMS trades at $23.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas FMS's P/E ratio is 11.80. In terms of profitability, PIII's ROE is +8.94%, compared to FMS's ROE of +0.07%. Regarding short-term risk, PIII is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check FMS's competition here
PIII vs SOLV Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, SOLV has a market cap of 12B. Regarding current trading prices, PIII is priced at $2.45, while SOLV trades at $68.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas SOLV's P/E ratio is 7.77. In terms of profitability, PIII's ROE is +8.94%, compared to SOLV's ROE of +0.37%. Regarding short-term risk, PIII is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check SOLV's competition here
PIII vs UHS Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, UHS has a market cap of 11.6B. Regarding current trading prices, PIII is priced at $2.45, while UHS trades at $180.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas UHS's P/E ratio is 7.88. In terms of profitability, PIII's ROE is +8.94%, compared to UHS's ROE of +0.21%. Regarding short-term risk, PIII is more volatile compared to UHS. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check UHS's competition here
PIII vs ENSG Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, ENSG has a market cap of 11.5B. Regarding current trading prices, PIII is priced at $2.45, while ENSG trades at $197.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas ENSG's P/E ratio is 34.04. In terms of profitability, PIII's ROE is +8.94%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, PIII is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check ENSG's competition here
PIII vs EHC Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, EHC has a market cap of 10.7B. Regarding current trading prices, PIII is priced at $2.45, while EHC trades at $106.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas EHC's P/E ratio is 19.23. In terms of profitability, PIII's ROE is +8.94%, compared to EHC's ROE of +0.24%. Regarding short-term risk, PIII is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check EHC's competition here
PIII vs DVA Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, DVA has a market cap of 10B. Regarding current trading prices, PIII is priced at $2.45, while DVA trades at $146.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas DVA's P/E ratio is 15.72. In terms of profitability, PIII's ROE is +8.94%, compared to DVA's ROE of -1.61%. Regarding short-term risk, PIII is more volatile compared to DVA. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check DVA's competition here
PIII vs OSH Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, PIII is priced at $2.45, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas OSH's P/E ratio is -17.65. In terms of profitability, PIII's ROE is +8.94%, compared to OSH's ROE of +4.64%. Regarding short-term risk, PIII is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check OSH's competition here
PIII vs LHCG Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, PIII is priced at $2.45, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas LHCG's P/E ratio is 82.83. In terms of profitability, PIII's ROE is +8.94%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, PIII is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check LHCG's competition here
PIII vs CHE Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, CHE has a market cap of 5.2B. Regarding current trading prices, PIII is priced at $2.45, while CHE trades at $374.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas CHE's P/E ratio is 20.54. In terms of profitability, PIII's ROE is +8.94%, compared to CHE's ROE of +0.24%. Regarding short-term risk, PIII is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check CHE's competition here
PIII vs OPCH Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, OPCH has a market cap of 4.4B. Regarding current trading prices, PIII is priced at $2.45, while OPCH trades at $27.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas OPCH's P/E ratio is 21.97. In terms of profitability, PIII's ROE is +8.94%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, PIII is more volatile compared to OPCH. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check OPCH's competition here
PIII vs MMED Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, MMED has a market cap of 4.3B. Regarding current trading prices, PIII is priced at $2.45, while MMED trades at $15.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas MMED's P/E ratio is -16.18. In terms of profitability, PIII's ROE is +8.94%, compared to MMED's ROE of -0.07%. Regarding short-term risk, PIII is more volatile compared to MMED. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check MMED's competition here
PIII vs AMED Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, PIII is priced at $2.45, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas AMED's P/E ratio is 39.30. In terms of profitability, PIII's ROE is +8.94%, compared to AMED's ROE of +0.09%. Regarding short-term risk, PIII is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check AMED's competition here
PIII vs BKD Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, BKD has a market cap of 3.3B. Regarding current trading prices, PIII is priced at $2.45, while BKD trades at $14.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas BKD's P/E ratio is -12.44. In terms of profitability, PIII's ROE is +8.94%, compared to BKD's ROE of -5.24%. Regarding short-term risk, PIII is more volatile compared to BKD. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check BKD's competition here
PIII vs LFST Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, LFST has a market cap of 2.5B. Regarding current trading prices, PIII is priced at $2.45, while LFST trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas LFST's P/E ratio is 325.50. In terms of profitability, PIII's ROE is +8.94%, compared to LFST's ROE of +0.01%. Regarding short-term risk, PIII is more volatile compared to LFST. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check LFST's competition here
PIII vs NHC Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, NHC has a market cap of 2.5B. Regarding current trading prices, PIII is priced at $2.45, while NHC trades at $159.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas NHC's P/E ratio is 21.28. In terms of profitability, PIII's ROE is +8.94%, compared to NHC's ROE of +0.12%. Regarding short-term risk, PIII is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check NHC's competition here
PIII vs ACHC Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, ACHC has a market cap of 2.4B. Regarding current trading prices, PIII is priced at $2.45, while ACHC trades at $26.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas ACHC's P/E ratio is -2.18. In terms of profitability, PIII's ROE is +8.94%, compared to ACHC's ROE of -0.39%. Regarding short-term risk, PIII is more volatile compared to ACHC. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check ACHC's competition here
PIII vs SEM Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, SEM has a market cap of 2B. Regarding current trading prices, PIII is priced at $2.45, while SEM trades at $16.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas SEM's P/E ratio is 14.14. In terms of profitability, PIII's ROE is +8.94%, compared to SEM's ROE of +0.09%. Regarding short-term risk, PIII is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check SEM's competition here
PIII vs MD Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, MD has a market cap of 1.9B. Regarding current trading prices, PIII is priced at $2.45, while MD trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas MD's P/E ratio is 11.66. In terms of profitability, PIII's ROE is +8.94%, compared to MD's ROE of +0.20%. Regarding short-term risk, PIII is more volatile compared to MD. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check MD's competition here
PIII vs AMEH Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, PIII is priced at $2.45, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas AMEH's P/E ratio is 39.25. In terms of profitability, PIII's ROE is +8.94%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, PIII is more volatile compared to AMEH. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check AMEH's competition here
PIII vs ADUS Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, ADUS has a market cap of 1.7B. Regarding current trading prices, PIII is priced at $2.45, while ADUS trades at $93.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas ADUS's P/E ratio is 17.86. In terms of profitability, PIII's ROE is +8.94%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, PIII is more volatile compared to ADUS. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check ADUS's competition here
PIII vs SGRY Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, SGRY has a market cap of 1.7B. Regarding current trading prices, PIII is priced at $2.45, while SGRY trades at $13.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas SGRY's P/E ratio is -21.48. In terms of profitability, PIII's ROE is +8.94%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, PIII is more volatile compared to SGRY. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check SGRY's competition here
PIII vs ASTH Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, ASTH has a market cap of 1.5B. Regarding current trading prices, PIII is priced at $2.45, while ASTH trades at $28.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas ASTH's P/E ratio is 63.20. In terms of profitability, PIII's ROE is +8.94%, compared to ASTH's ROE of +0.03%. Regarding short-term risk, PIII is more volatile compared to ASTH. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check ASTH's competition here
PIII vs AVAH Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, AVAH has a market cap of 1.4B. Regarding current trading prices, PIII is priced at $2.45, while AVAH trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas AVAH's P/E ratio is 6.31. In terms of profitability, PIII's ROE is +8.94%, compared to AVAH's ROE of +9.53%. Regarding short-term risk, PIII is more volatile compared to AVAH. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check AVAH's competition here
PIII vs ARDT Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, ARDT has a market cap of 1.3B. Regarding current trading prices, PIII is priced at $2.45, while ARDT trades at $9.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas ARDT's P/E ratio is 9.81. In terms of profitability, PIII's ROE is +8.94%, compared to ARDT's ROE of +0.10%. Regarding short-term risk, PIII is more volatile compared to ARDT. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check ARDT's competition here
PIII vs HCSG Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, HCSG has a market cap of 1.3B. Regarding current trading prices, PIII is priced at $2.45, while HCSG trades at $19.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas HCSG's P/E ratio is 23.49. In terms of profitability, PIII's ROE is +8.94%, compared to HCSG's ROE of +0.12%. Regarding short-term risk, PIII is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check HCSG's competition here
PIII vs BKDT Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, PIII is priced at $2.45, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas BKDT's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to BKDT's ROE of -5.24%. Regarding short-term risk, PIII is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check BKDT's competition here
PIII vs USPH Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, PIII is priced at $2.45, while USPH trades at $76.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas USPH's P/E ratio is 54.35. In terms of profitability, PIII's ROE is +8.94%, compared to USPH's ROE of +0.03%. Regarding short-term risk, PIII is more volatile compared to USPH. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check USPH's competition here
PIII vs INNV Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, INNV has a market cap of 1.1B. Regarding current trading prices, PIII is priced at $2.45, while INNV trades at $8.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas INNV's P/E ratio is 163.40. In terms of profitability, PIII's ROE is +8.94%, compared to INNV's ROE of -0.02%. Regarding short-term risk, PIII is more volatile compared to INNV. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check INNV's competition here
PIII vs PNTG Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, PIII is priced at $2.45, while PNTG trades at $30.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas PNTG's P/E ratio is 36.49. In terms of profitability, PIII's ROE is +8.94%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, PIII is more volatile compared to PNTG. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check PNTG's competition here
PIII vs TALK Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, TALK has a market cap of 863.8M. Regarding current trading prices, PIII is priced at $2.45, while TALK trades at $5.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas TALK's P/E ratio is 129.25. In terms of profitability, PIII's ROE is +8.94%, compared to TALK's ROE of +0.07%. Regarding short-term risk, PIII is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check TALK's competition here
PIII vs FSHCX Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, FSHCX has a market cap of 863.1M. Regarding current trading prices, PIII is priced at $2.45, while FSHCX trades at $99.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas FSHCX's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to FSHCX's ROE of N/A. Regarding short-term risk, PIII is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check FSHCX's competition here
PIII vs AMN Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, AMN has a market cap of 724.7M. Regarding current trading prices, PIII is priced at $2.45, while AMN trades at $19.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas AMN's P/E ratio is -7.56. In terms of profitability, PIII's ROE is +8.94%, compared to AMN's ROE of -0.15%. Regarding short-term risk, PIII is more volatile compared to AMN. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check AMN's competition here
PIII vs EHAB Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, EHAB has a market cap of 705.6M. Regarding current trading prices, PIII is priced at $2.45, while EHAB trades at $13.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas EHAB's P/E ratio is -154.56. In terms of profitability, PIII's ROE is +8.94%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, PIII is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check EHAB's competition here
PIII vs SNDA Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, SNDA has a market cap of 621.8M. Regarding current trading prices, PIII is priced at $2.45, while SNDA trades at $34.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas SNDA's P/E ratio is -8.15. In terms of profitability, PIII's ROE is +8.94%, compared to SNDA's ROE of -0.81%. Regarding short-term risk, PIII is more volatile compared to SNDA. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check SNDA's competition here
PIII vs CMPS Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, CMPS has a market cap of 552.5M. Regarding current trading prices, PIII is priced at $2.45, while CMPS trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas CMPS's P/E ratio is -1.87. In terms of profitability, PIII's ROE is +8.94%, compared to CMPS's ROE of -3.36%. Regarding short-term risk, PIII is more volatile compared to CMPS. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check CMPS's competition here
PIII vs MCTA Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, PIII is priced at $2.45, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas MCTA's P/E ratio is 419.36. In terms of profitability, PIII's ROE is +8.94%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, PIII is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check MCTA's competition here
PIII vs CYH Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, CYH has a market cap of 427M. Regarding current trading prices, PIII is priced at $2.45, while CYH trades at $3.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas CYH's P/E ratio is 0.82. In terms of profitability, PIII's ROE is +8.94%, compared to CYH's ROE of -0.32%. Regarding short-term risk, PIII is more volatile compared to CYH. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check CYH's competition here
PIII vs AUNA Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, AUNA has a market cap of 409.3M. Regarding current trading prices, PIII is priced at $2.45, while AUNA trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas AUNA's P/E ratio is 14.55. In terms of profitability, PIII's ROE is +8.94%, compared to AUNA's ROE of +0.06%. Regarding short-term risk, PIII is more volatile compared to AUNA. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check AUNA's competition here
PIII vs AGL Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, AGL has a market cap of 375.5M. Regarding current trading prices, PIII is priced at $2.45, while AGL trades at $22.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas AGL's P/E ratio is -0.92. In terms of profitability, PIII's ROE is +8.94%, compared to AGL's ROE of -1.17%. Regarding short-term risk, PIII is more volatile compared to AGL. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check AGL's competition here
PIII vs TOI Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, TOI has a market cap of 334.1M. Regarding current trading prices, PIII is priced at $2.45, while TOI trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas TOI's P/E ratio is -6.26. In terms of profitability, PIII's ROE is +8.94%, compared to TOI's ROE of +7.60%. Regarding short-term risk, PIII is more volatile compared to TOI. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check TOI's competition here
PIII vs CCRN Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, CCRN has a market cap of 315.8M. Regarding current trading prices, PIII is priced at $2.45, while CCRN trades at $9.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas CCRN's P/E ratio is -3.33. In terms of profitability, PIII's ROE is +8.94%, compared to CCRN's ROE of -0.24%. Regarding short-term risk, PIII is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check CCRN's competition here
PIII vs CSU Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, PIII is priced at $2.45, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas CSU's P/E ratio is 0.67. In terms of profitability, PIII's ROE is +8.94%, compared to CSU's ROE of -2.10%. Regarding short-term risk, PIII is more volatile compared to CSU. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check CSU's competition here
PIII vs AONC Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, AONC has a market cap of 216.4M. Regarding current trading prices, PIII is priced at $2.45, while AONC trades at $7.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas AONC's P/E ratio is -8.31. In terms of profitability, PIII's ROE is +8.94%, compared to AONC's ROE of +0.06%. Regarding short-term risk, PIII is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check AONC's competition here
PIII vs AIRS Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, AIRS has a market cap of 184.8M. Regarding current trading prices, PIII is priced at $2.45, while AIRS trades at $2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas AIRS's P/E ratio is -13.79. In terms of profitability, PIII's ROE is +8.94%, compared to AIRS's ROE of -0.14%. Regarding short-term risk, PIII is more volatile compared to AIRS. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check AIRS's competition here
PIII vs JYNT Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, JYNT has a market cap of 128.6M. Regarding current trading prices, PIII is priced at $2.45, while JYNT trades at $9.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas JYNT's P/E ratio is -449.00. In terms of profitability, PIII's ROE is +8.94%, compared to JYNT's ROE of +0.14%. Regarding short-term risk, PIII is more volatile compared to JYNT. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check JYNT's competition here
PIII vs NAKAW Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, PIII is priced at $2.45, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas NAKAW's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to NAKAW's ROE of -0.21%. Regarding short-term risk, PIII is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check NAKAW's competition here
PIII vs FVE Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, PIII is priced at $2.45, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas FVE's P/E ratio is -5.64. In terms of profitability, PIII's ROE is +8.94%, compared to FVE's ROE of -0.15%. Regarding short-term risk, PIII is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check FVE's competition here
PIII vs KDLYW Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, PIII is priced at $2.45, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas KDLYW's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to KDLYW's ROE of -0.21%. Regarding short-term risk, PIII is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check KDLYW's competition here
PIII vs BTMD Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, BTMD has a market cap of 82M. Regarding current trading prices, PIII is priced at $2.45, while BTMD trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas BTMD's P/E ratio is 2.51. In terms of profitability, PIII's ROE is +8.94%, compared to BTMD's ROE of -0.35%. Regarding short-term risk, PIII is more volatile compared to BTMD. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check BTMD's competition here
PIII vs DCGO Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, DCGO has a market cap of 53.2M. Regarding current trading prices, PIII is priced at $2.45, while DCGO trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas DCGO's P/E ratio is -0.28. In terms of profitability, PIII's ROE is +8.94%, compared to DCGO's ROE of -0.71%. Regarding short-term risk, PIII is more volatile compared to DCGO. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check DCGO's competition here
PIII vs ALR Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, PIII is priced at $2.45, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas ALR's P/E ratio is -1.11. In terms of profitability, PIII's ROE is +8.94%, compared to ALR's ROE of -0.15%. Regarding short-term risk, PIII is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check ALR's competition here
PIII vs IMAC Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, PIII is priced at $2.45, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas IMAC's P/E ratio is -2.27. In terms of profitability, PIII's ROE is +8.94%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, PIII is more volatile compared to IMAC. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check IMAC's competition here
PIII vs CCEL Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, CCEL has a market cap of 29.6M. Regarding current trading prices, PIII is priced at $2.45, while CCEL trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas CCEL's P/E ratio is -12.23. In terms of profitability, PIII's ROE is +8.94%, compared to CCEL's ROE of +0.15%. Regarding short-term risk, PIII is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check CCEL's competition here
PIII vs CANO-WT Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, PIII is priced at $2.45, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, PIII is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check CANO-WT's competition here
PIII vs AIH Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, PIII is priced at $2.45, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas AIH's P/E ratio is -2.78. In terms of profitability, PIII's ROE is +8.94%, compared to AIH's ROE of +1.16%. Regarding short-term risk, PIII is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check AIH's competition here
PIII vs CANO Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, PIII is priced at $2.45, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas CANO's P/E ratio is -0.01. In terms of profitability, PIII's ROE is +8.94%, compared to CANO's ROE of -1.49%. Regarding short-term risk, PIII is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check CANO's competition here
PIII vs FTRP Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, PIII is priced at $2.45, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas FTRP's P/E ratio is -1.22. In terms of profitability, PIII's ROE is +8.94%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, PIII is more volatile compared to FTRP. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check FTRP's competition here
PIII vs AMS Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, AMS has a market cap of 8.6M. Regarding current trading prices, PIII is priced at $2.45, while AMS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas AMS's P/E ratio is -5.65. In terms of profitability, PIII's ROE is +8.94%, compared to AMS's ROE of -0.06%. Regarding short-term risk, PIII is more volatile compared to AMS. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check AMS's competition here
PIII vs MODV Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, PIII is priced at $2.45, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas MODV's P/E ratio is -0.03. In terms of profitability, PIII's ROE is +8.94%, compared to MODV's ROE of +1.84%. Regarding short-term risk, PIII is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check MODV's competition here
PIII vs SYRA Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, SYRA has a market cap of 5.8M. Regarding current trading prices, PIII is priced at $2.45, while SYRA trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas SYRA's P/E ratio is -3.68. In terms of profitability, PIII's ROE is +8.94%, compared to SYRA's ROE of -0.39%. Regarding short-term risk, PIII is more volatile compared to SYRA. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check SYRA's competition here
PIII vs GBNH Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, PIII is priced at $2.45, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas GBNH's P/E ratio is -0.06. In terms of profitability, PIII's ROE is +8.94%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, PIII is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check GBNH's competition here
PIII vs RHE Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, PIII is priced at $2.45, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas RHE's P/E ratio is -1.79. In terms of profitability, PIII's ROE is +8.94%, compared to RHE's ROE of -0.00%. Regarding short-term risk, PIII is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check RHE's competition here
PIII vs RHE-PA Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, PIII is priced at $2.45, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, PIII's ROE is +8.94%, compared to RHE-PA's ROE of -9.49%. Regarding short-term risk, PIII is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check RHE-PA's competition here
PIII vs TOIIW Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, TOIIW has a market cap of 4.8M. Regarding current trading prices, PIII is priced at $2.45, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas TOIIW's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to TOIIW's ROE of +7.60%. Regarding short-term risk, PIII is more volatile compared to TOIIW. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check TOIIW's competition here
PIII vs ATIP Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, PIII is priced at $2.45, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas ATIP's P/E ratio is -0.03. In terms of profitability, PIII's ROE is +8.94%, compared to ATIP's ROE of +2.05%. Regarding short-term risk, PIII is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check ATIP's competition here
PIII vs IMACW Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, PIII is priced at $2.45, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas IMACW's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, PIII is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check IMACW's competition here
PIII vs MNDR Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, MNDR has a market cap of 740K. Regarding current trading prices, PIII is priced at $2.45, while MNDR trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas MNDR's P/E ratio is -0.35. In terms of profitability, PIII's ROE is +8.94%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, PIII is more volatile compared to MNDR. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check MNDR's competition here
PIII vs CCM Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, CCM has a market cap of 583.9K. Regarding current trading prices, PIII is priced at $2.45, while CCM trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas CCM's P/E ratio is -0.73. In terms of profitability, PIII's ROE is +8.94%, compared to CCM's ROE of +0.04%. Regarding short-term risk, PIII is more volatile compared to CCM. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check CCM's competition here
PIII vs TALKW Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, TALKW has a market cap of 359K. Regarding current trading prices, PIII is priced at $2.45, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas TALKW's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to TALKW's ROE of +0.07%. Regarding short-term risk, PIII is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check TALKW's competition here
PIII vs BACK Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, BACK has a market cap of 208.2K. Regarding current trading prices, PIII is priced at $2.45, while BACK trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas BACK's P/E ratio is -0.02. In terms of profitability, PIII's ROE is +8.94%, compared to BACK's ROE of +1.05%. Regarding short-term risk, PIII is more volatile compared to BACK. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check BACK's competition here
PIII vs NVOS Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, NVOS has a market cap of 69.1K. Regarding current trading prices, PIII is priced at $2.45, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas NVOS's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, PIII is more volatile compared to NVOS. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check NVOS's competition here
PIII vs NIVFW Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, NIVFW has a market cap of 30.2K. Regarding current trading prices, PIII is priced at $2.45, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas NIVFW's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, PIII is more volatile compared to NIVFW. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check NIVFW's competition here
PIII vs PIIIW Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, PIIIW has a market cap of 17.7K. Regarding current trading prices, PIII is priced at $2.45, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas PIIIW's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to PIIIW's ROE of +8.94%. Regarding short-term risk, PIII is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check PIIIW's competition here
PIII vs IONM Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, IONM has a market cap of 1.6K. Regarding current trading prices, PIII is priced at $2.45, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas IONM's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to IONM's ROE of +5.28%. Regarding short-term risk, PIII is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check IONM's competition here
PIII vs SLHGP Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, PIII is priced at $2.45, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, PIII's ROE is +8.94%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, PIII is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check SLHGP's competition here
PIII vs TLMD Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, TLMD has a market cap of 0. Regarding current trading prices, PIII is priced at $2.45, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas TLMD's P/E ratio is -1.60. In terms of profitability, PIII's ROE is +8.94%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, PIII is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check TLMD's competition here
PIII vs SLHG Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, SLHG has a market cap of 0. Regarding current trading prices, PIII is priced at $2.45, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas SLHG's P/E ratio is -1.48. In terms of profitability, PIII's ROE is +8.94%, compared to SLHG's ROE of N/A. Regarding short-term risk, PIII is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check SLHG's competition here
PIII vs AFAM Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, AFAM has a market cap of 0. Regarding current trading prices, PIII is priced at $2.45, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas AFAM's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, PIII is more volatile compared to AFAM. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check AFAM's competition here
PIII vs NFH Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, NFH has a market cap of 0. Regarding current trading prices, PIII is priced at $2.45, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas NFH's P/E ratio is -19.75. In terms of profitability, PIII's ROE is +8.94%, compared to NFH's ROE of -0.06%. Regarding short-term risk, PIII is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check NFH's competition here
PIII vs DVCR Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, DVCR has a market cap of 0. Regarding current trading prices, PIII is priced at $2.45, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas DVCR's P/E ratio is 28.34. In terms of profitability, PIII's ROE is +8.94%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, PIII is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check DVCR's competition here
PIII vs TLMDW Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, PIII is priced at $2.45, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas TLMDW's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, PIII is more volatile compared to TLMDW. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check TLMDW's competition here
PIII vs DCGOW Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, PIII is priced at $2.45, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas DCGOW's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to DCGOW's ROE of -0.71%. Regarding short-term risk, PIII is more volatile compared to DCGOW. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check DCGOW's competition here
PIII vs HNGR Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, HNGR has a market cap of 0. Regarding current trading prices, PIII is priced at $2.45, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas HNGR's P/E ratio is 19.71. In terms of profitability, PIII's ROE is +8.94%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, PIII is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check HNGR's competition here
PIII vs KND Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, KND has a market cap of 0. Regarding current trading prices, PIII is priced at $2.45, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas KND's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to KND's ROE of -0.53%. Regarding short-term risk, PIII is more volatile compared to KND. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check KND's competition here
PIII vs TVTY Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, TVTY has a market cap of 0. Regarding current trading prices, PIII is priced at $2.45, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas TVTY's P/E ratio is 19.06. In terms of profitability, PIII's ROE is +8.94%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, PIII is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for PIII.Check TVTY's competition here
PIII vs ATIP-WT Comparison April 2026
PIII plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PIII stands at 8.1M. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, PIII is priced at $2.45, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PIII currently has a P/E ratio of -0.05, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, PIII's ROE is +8.94%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, PIII is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PIII.Check ATIP-WT's competition here